ALX Oncology Holdings Inc.

ALXONASDAQBeobachtung

US$1.99

-0.5 % today

COMPANY DATA

Sector: HealthcareIndustry: BiotechnologyCountry: USCEO: Jason LettmannEmployees: 48Market cap: 268 MIPO: 17/07/2020Web: www.alxoncology.com

Das in South San Francisco ansässige ALX Oncology Holdings Inc. ist im Bereich der Healthcare-Branche tätig und konzentriert sich auf die Entwicklung von Immunonkologie-Therapien für Krebspatienten. Mit dem Tickersymbol ALXO treibt das Unternehmen klinische Programme voran, wobei Evorpacept als zentraler…

Brief assessment by a strategy agent, last updated on 03/08/2026. Not investment advice.

PRICE HISTORY

26/08/25+80.9 %26/08/26

1D

-0.5 %

1W

-3.4 %

1M

-1.5 %

6M

-17.8 %

YTD

+76.1 %

1Y

+80.9 %

2Y

-22.6 %

5Y

-97.3 %

10Y

–

EARNINGS

Next earnings date

06/11/2026 (in 72 days)

Volatility around earnings

~6% stronger price swings than usual

SCORES

Valuation

Valued significantly cheaper than its own historical average.

Why this value? Details with Pro only.

Trend

Clear downtrend.

Why this value? Details with Pro only.

Quality

Average balance sheet quality.

Why this value? Details with Pro only.

Dividend

Not enough data yet for an assessment.

Growth

Weak growth or expensive relative to it.

Why this value? Details with Pro only.

Insider

No notable insider activity.

Why this value? Details with Pro only.

Earnings

Roughly meets expectations.

Why this value? Details with Pro only.

Revisions

Significantly more upgrades than downgrades from analysts recently.

Why this value? Details with Pro only.

Sentiment

Not enough data yet for an assessment.

Short Pressure

Persistently high short volume ratio, partly with a Reg SHO threshold listing.

Why this value? Details with Pro only.

Register for free

Unlock all 9 scores

4 credits free on registration
Access to virtual portfolios and watchlist
No credit card, no payment details needed
No subscription, no minimum term
Our own servers in Germany, no US cloud

Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.

ASK THE AGENTS ABOUT ALXO

ANALYST ASSESSMENT

PRICE TARGET LOW

US$1.50

CONSENSUS

US$17.90

MEDIAN

US$21.00

PRICE TARGET HIGH

US$38.00

0

STRONG BUY

6

BUY

1

HOLD

0

SELL

0

STRONG SELL

7

TOTAL · Buy

DATE	ANALYST FIRM	RATING	ACTION
10/03/2026	HC Wainwright & Co.	Buy	maintain
05/02/2026	Piper Sandler	Overweight	maintain
21/05/2025	UBS	Buy	maintain
09/05/2025	HC Wainwright & Co.	Buy	maintain
07/03/2025	Stifel	Hold	maintain
07/03/2025	HC Wainwright & Co.	Buy	maintain
06/03/2025	Piper Sandler	Overweight	maintain
06/03/2025	Jefferies	Hold → Buy	upgrade

METRICS

P/E

-1.76

P/B

1.98

EV/EBITDA

-3.23

RETURN ON EQUITY

-13.2 %

NET MARGIN

0 %

DEBT/EQUITY

0.07

DIVIDEND YIELD

0 %

AS OF

30/06/2026

FREE FLOAT & LIQUIDITY

FREE FLOAT

79.5 %

FLOAT SHARES

107,016,542

AVG. DAILY VOLUME (30D)

912,115

INSIDER TRANSACTIONS (SEC)

DATE	INSIDER	ROLE	TRANSACTION	SHARES	PRICE	PLAN TYPE
18/08/2026	Wong Shelly	Officer	Sale	573	1.93	Spontaneous
18/08/2026	Lettmann Jason	Officer	Sale	2,230	1.93	Spontaneous
06/07/2026	Wong Shelly	Officer	Sale	1,404	2.04	Spontaneous

ATTENTION

Price since yesterday: -0.5%

Search (Google Trends)

19/0727/0704/08

INSTITUTIONAL HOLDERS

FUND / INSTITUTION	SHARES	CHANGE	AS OF
NINE MASTS CAPITAL Ltd	0	-20,623	30/06/2026
Point72 Asset Management, L.P.	0	-41,095	30/06/2026
JANE STREET GROUP, LLC	0	-95,101	30/06/2026
Optiver Holding B.V.	0	-27	30/06/2026
Qube Research & Technologies Ltd	0	-107,647	30/06/2026

Page 1 / 3

Not investment advice. Past performance is not an indicator of future results.